bronchitis%20-%20chronic%20in%20acute%20exacerbation
BRONCHITIS - CHRONIC IN ACUTE EXACERBATION

Chronic bronchitis is an infection of the trachea and bronchi for at least 3 consecutive months for more than 2 consecutive years.
The patient experiences symptoms of increase in dyspnea, sputum volume and sputum purulence over baseline on most days.

Diagnosis is basically based on clinical presentation.

Definition

  • Chronic bronchitis is a clinical diagnosis of sputum expectoration on most days during at least 3 consecutive months for ≥2 consecutive years

Signs and Symptoms

  • Symptoms of exacerbation are increase in dyspnea, sputum volume and sputum purulence over baseline

Risk Factors for Exacerbations

  • Tracheobronchial infections (eg influenza, streptococcal infection)
  • Environmental exposures (eg air pollution)
  • Noncompliance with inhaled bronchodilator therapy or pulmonary rehabilitation program
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
23 Nov 2018
Initial acute respiratory illness (ARI) admissions related to human adenovirus (HAdV), human metapneumovirus (hMPV) and human rhinovirus (HRV) occurring during early infancy increase the risk of subsequent ARI-related readmission, a recent study has shown.
Jairia Dela Cruz, 08 Jan 2020
In chronic obstructive pulmonary disease (COPD) patients initiating inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) combinations, both budesonide/formoterol (FOR) dry-powder inhalers and beclomethasone/FOR metered-dose inhalers pose lower risks of severe pneumonia and severe adverse events compared with fluticasone/salmeterol delivered using the same type of inhaler, as reported in a recent study.
Roshini Claire Anthony, 19 Dec 2019

First-line treatment with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) dacomitinib demonstrated persistent survival benefit in patients with EGFR-positive advanced non-small cell lung cancer (NSCLC), according to updated results from the phase III ARCHER 1050* trial.

Pearl Toh, 03 Dec 2018
Sequential treatment with afatinib followed by osimertinib enables prolonged chemotherapy-free treatment while sustaining clinical benefit in patients with EGFR-mutation positive (EGFR+) non-small–cell lung cancer (NSCLC) who acquire T790M mutation, according to the real-world retrospective GioTag study presented at ESMO Asia 2018.